共 16 条
- [2] Long Term Effectiveness and Safety of Intracavernosal Botulinum Toxin A as an Add-on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 Injections for Erectile Dysfunction JOURNAL OF SEXUAL MEDICINE, 2022, 19 (01): : 83 - 89
- [3] Re: Long Term Effectiveness and Safety of Intracavernosal Botulinum Toxin A as an Add-on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 Injections for Erectile Dysfunction Editorial Comment JOURNAL OF UROLOGY, 2022, 207 (05): : 1138 - 1139
- [4] LONG TERM EFFECTIVENESS AND SAFETY OF INTRACAVERNOSAL BOTULINUM TOXIN A AS AN ADD-ON THERAPY TOPHOSPHOSDIESTERASE TYPE 5 INHIBITORS OR PROSTAGLANDIN E1 INJECTIONS FOR ERECTILE DYSFUNCTION - A CASE SERIES STUDY JOURNAL OF SEXUAL MEDICINE, 2022, 19 (11): : S11 - S11
- [6] Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction International Journal of Impotence Research, 1997, 9 : 225 - 229
- [8] Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction International Journal of Impotence Research, 2006, 18 : 180 - 185
- [10] Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E1 intracavernosal injection therapy to oral sildenafil citrate International Journal of Impotence Research, 2003, 15 : 444 - 449